Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZL-1310 |
| Synonyms | |
| Therapy Description |
ZL-1310 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLL3 linked to a camptothecin derivative, which potentially inhibits tumor growth (ESMO Open, Volume 9, 102891). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZL-1310 | ZL1310|ZL 1310|YL212|YL 212|YL-212|ADC SC-002 | DLL3 Antibody 10 | ZL-1310 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLL3 linked to a camptothecin derivative, which potentially inhibits tumor growth (ESMO Open, Volume 9, 102891). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06179069 | Phase I | Atezolizumab + ZL-1310 Atezolizumab + Carboplatin + ZL-1310 ZL-1310 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Recruiting | USA | ESP | 1 |
| NCT06885281 | Phase Ib/II | ZL-1310 | A Study of ZL-1310 in Participants With Selected Solid Tumors | Recruiting | USA | 1 |